SEC Form 4 · accession 0001209191-15-059225
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
Jun 30, 2015
Accepted (ET)
Jul 2, 2015 · 8:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 30, 2015 | J | 1,000 | $14.16 | A | 1,000 | D | |
| Common Stock | holding | — | — | — | 205,370 | D | ||
| Common StockF2 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired by the Reporting Person under the Issuer 2014 Employee Stock Purchase Plan on June 30, 2015 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.